生物公司任命Shreehas Tambe为新首席执行官,生效时间:2026年4月1日. Biocon appoints Shreehas Tambe as new CEO, effective April 1, 2026.

生物公司任命Shreehas Tambe为其新任首席执行官和董事总经理,自2026年4月1日起生效. Biocon has appointed Shreehas Tambe as its new CEO and Managing Director, effective April 1, 2026. 作为公司30年资深员工, 他将领导该公司生物仿制药和全方位医疗产品部门整合到一个统一的全球生物制药平台. Tambe, a 30-year company veteran, will lead the integration of the company's biosimilars and generics divisions into a unified global biopharma platform. 执行董事长Kiran Mazumdar-Shaw宣布的领导层变化旨在加强业务并扩大公司在瘤和糖尿病治疗等高增长市场的覆盖范围. The leadership change, announced by Executive Chairperson Kiran Mazumdar-Shaw, aims to strengthen operations and expand the company's reach in high-growth markets like oncology and diabetes treatments.